ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Utilizing its proprietary protein engineering platform, ProMIS specializes in the identification and targeting of misfolded proteins associated with these diseases, which enhances the safety and efficacy of its drug candidates. The company boasts a robust and diverse pipeline of candidates in various stages of development, positioning it favorably to address significant unmet medical needs in the biopharmaceutical arena, making it a compelling investment opportunity for institutional investors seeking growth in the healthcare sector.
| Revenue (TTM) | 7,560 |
| Gross Profit (TTM) | $-33.38M |
| EBITDA | $-13.31M |
| Operating Margin | 0.00% |
| Return on Equity | -172.30% |
| Return on Assets | -81.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.77 |
| Price-to-Book | 2.19 |
| Price-to-Sales (TTM) | 4016.22 |
| EV/Revenue | 4004.98 |
| EV/EBITDA | -1.74 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.97M |
| Float | $4.60M |
| % Insiders | 11.87% |
| % Institutions | 77.25% |
Volatility is currently contracting
Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.
Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer's disease and early Alzheimer's disease.
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biopharmaceutical company developing therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of its lead drug candidate, PMN310, in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease (AD). In the blinded interim analysis evaluating 136 AD patients, PMN310 was observed to have a favorable safety profile across all genotypes, with no cases of amyloid-related imaging abnormalities-edema (ARIA-E) reported as of the data cutoff date, and early, directionally consistent movement in disease-relevant biomarkers potentially reflective of the randomization pattern.
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion Leaders (KOLs) Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco. They will join company leadership to discuss the Company's six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients with early Alzheimer's disease (AD).
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers
The mean of analysts' price targets for Promis Neurosciences (PMN) points to a 230.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Promis Neurosciences (PMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 231.8% in Promis Neurosciences (PMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PMN and any ticker you trade — then tracks every position and per-strategy win rate.
